ANNX 241220 5.00C (ANNX241220C5000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

ANNX241220C5000

Watchlist

0.23
-0.17-42.50%

15min DelayClose Dec 13 16:00 ET

0.29High0.23Low

Intraday

5D
Daily

News

Annexon Insider Buyers Pleased With US$571k Return On Investment
Simply Wall StDec 13 05:06 ET
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors With ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting
GlobeNewswireDec 5 08:00 ET
Analysts Are Bullish on These Healthcare Stocks: Annexon Biosciences (ANNX), Mirum Pharmaceuticals (MIRM)
TipRanksNov 21 07:11 ET · Ratings
Express News | Annexon Inc : JP Morgan Cuts Target Price to $9 From $11
ReutersNov 20 00:28 ET
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswireNov 15 16:59 ET
Express News | Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
ReutersNov 15 16:59 ET

Comments

Jaguar8

Oct 21 19:01

NEWS

$Annexon (ANNX.US)$
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
Annexon presented new Phase 2 datafor ANX007 in geographic atrophy (GA) due to dry age-related macular degeneration (AMD) at the American Academy of Ophthalmology 2024 meeting. The study showed enhanced vision protection and greater preservation of central photoreceptor cells in patients with less advanced disease. Ke...

Trytosaveabit

Oct 8 16:47

Time to start watching for data release again! Hehehe!

$Annexon (ANNX.US)$ Looking for this soon.
((((((. ANX1502 in CAD: POC trial evaluating the pharmacodynamics and efficacy of an oral tablet formulation in CAD anticipated to provide initial data in the fourth quarter of 2024 )))))

Trytosaveabit

Aug 13 04:34

Note the dates!

$Annexon (ANNX.US)$ Key Anticipated Milestones for Flagship Programs
*ANX005 in GBS: Initial topline data from RWE comparability protocol with IGOS now expected by year-end 2024 to support a planned BLA submission in the first half of 2025
*ANX1502 in CAD: POC trial evaluating the pharmacodynamics and efficacy of an oral tablet formulation in CAD anticipated to provide initial data in the fourth quarter of 2024

Jaguar8

Jul 11 17:10

NEWS

$Annexon (ANNX.US)$
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
Annexon will present additional data from its Phase 2 ARCHER trial on ANX007 at the 42nd ASRS Annual Scientific Meeting in Stockholm, Sweden from July 17-20, 2024. The presentations will highlight the protective effects of ANX007 on visual acuity and anatomical measures in patients with geographic atroph...

Trytosaveabit

Jun 25 16:07

$Annexon (ANNX.US)$ Did anyone remember to be watching for this? I told Y’all on the 18th to be looking! Hehehe